Diffuse Worsening Pain on Long-Term Opioids: Hyperalgesia, Tolerance, or Progression?
A 44-year-old woman developed L5 radiculopathy after a lifting injury three years ago. She had partial relief after laminectomy, and over two years her regimen was escalated to oxycodone ER 40 mg twice daily plus oxycodone IR 10 mg every 6 hours as needed, roughly 130 MME/day. In the past three months her pain has spread from the left leg to both legs, the back, and the abdomen. She describes burning everywhere and cannot tolerate bedsheets against her skin. There is no new weakness, and MRI six weeks ago shows stable postoperative changes with no recurrent disc. Two prior dose increases each produced about ten days of relief followed by pain worse than before. Examination shows diffuse hyperalgesia and allodynia extending beyond any dermatome; pupils are 5 mm and reactive; there is no rhinorrhea, yawning, or piloerection. Reflexes and strength are unchanged.
1. Construct a differential for her worsening pain and identify which historical and examination features argue for and against each entity.
Read the worked answer
Differential: opioid-induced hyperalgesia (OIH), pharmacologic tolerance, disease progression, opioid withdrawal, and untreated central or mood contributors.
- OIH - favored. Pain has spread well outside the original L5 distribution, allodynia is diffuse and non-dermatomal, and each escalation produced brief relief followed by worsening. That paradoxical dose-response is the signature. Mild mydriasis without autonomic signs is compatible but nonspecific (anticholinergic burden, anxiety).
- Tolerance - not the driver. Tolerance means a given dose loses effect; it does not cause spreading allodynia or pain worse than baseline. It would predict benefit from escalation, which she did not sustain.
- Disease progression - argued against. MRI is stable, strength and reflexes are unchanged, and the distribution is non-anatomic. It cannot be excluded with certainty but does not explain the diffuse cutaneous findings.
- Withdrawal - argued against. No rhinorrhea, yawning, piloerection, diarrhea, or cramping, and she is taking a stable dose rather than running short.
- Central sensitization from untreated depression, sleep disruption, or deconditioning is a plausible contributor and should be screened rather than assumed.
The discriminating question is not "how much pain" but "does the pain behave like nociception?" Here it does not.
2. Explain the pharmacologic rationale for opioid-induced hyperalgesia and show how that mechanism changes your next step.
Read the worked answer
Sustained mu-opioid receptor activation produces pronociceptive adaptation at several levels:
- NMDA receptor–dependent central sensitization in dorsal horn neurons, with increased synaptic efficacy and expanded receptive fields - matching her spreading, non-dermatomal allodynia.
- Glial activation and neuroinflammation, with cytokine release that further lowers nociceptive thresholds.
- Upregulation of spinal dynorphin and enhanced descending facilitation from the rostral ventromedial medulla.
The mechanistic implication is counterintuitive and clinically decisive: more mu agonism is predicted to worsen, not improve, the pain. That reframes her request for an increase as a request that the pharmacology says will fail.
The same mechanism suggests rational alternatives:
- Dose reduction - the definitive test and treatment; improvement after lowering the dose supports the diagnosis.
- Rotation to an agent with NMDA antagonism or partial agonism - methadone (NMDA antagonism, but QT and accumulation risk) or buprenorphine (partial agonism, kappa antagonism, ceiling on respiratory depression, far easier to manage).
- Non-opioid adjuvants and behavioral treatment to reduce central amplification.
Ketamine has mechanistic appeal but should be reserved for refractory, closely monitored cases rather than used as an outpatient shortcut.
3. She asks for a dose increase. Outline your plan, including counseling and safety monitoring.
Read the worked answer
Do not increase the dose. Explain plainly: "When we raise the opioid, your pain briefly improves and then spreads further - that pattern tells me the medicine is now amplifying the pain rather than treating it." Frame reduction as treatment, not withdrawal of care.
Plan
- Convert to buprenorphine, either by direct transition from ~130 MME/day or by low-dose induction, which avoids a withdrawal storm and often improves both pain and function. Alternatively, taper the current opioid by roughly 5–10% per month with planned pauses.
- Never abrupt discontinuation; document the shared decision and the agreed pace.
- Add non-opioid therapy: duloxetine if no contraindication, topical agents for residual focal pain, physical therapy with graded exposure, and CBT for catastrophizing and insomnia.
- Co-prescribe naloxone and counsel the household.
Monitoring
- Follow-up every 2–4 weeks during the transition; ask about function and sleep, not just pain scores.
- PDMP and urine drug testing at baseline and periodically; check for sedative co-use.
- Screen for suicidality given the chronic pain and escalating distress; PHQ-9 at each visit.
- Reassess for OUD separately - her stable dosing and concordant testing argue against it, but that assessment must be explicit, not assumed.